Blujepa Shortage: What Providers and Prescribers Need to Know in 2026

Blujepa (Gepotidacin) represents the first FDA-approved triazaacenaphthylene antibiotic — a genuinely new mechanism of action in a landscape where antimicrobial resistance continues to narrow treatment options. Since its initial approval in March 2025 for uncomplicated UTIs and its expanded indication for uncomplicated urogenital gonorrhea in December 2025, clinicians have gained a valuable new tool.

However, patient access to Blujepa has been inconsistent. This briefing covers the current availability picture, prescribing implications, and practical resources to help your patients get their prescriptions filled.

Current Status: Is Blujepa in Shortage?

As of February 2026, Blujepa is not listed on the FDA Drug Shortages database. GSK continues to manufacture and distribute the product. The access challenges patients are experiencing stem from pharmacy-level stocking gaps rather than a manufacturing or supply-chain shortage.

This distinction matters for clinical decision-making: Blujepa is available — it just requires more effort to locate than established antibiotics.

Timeline of Key Events

• March 2025: FDA approval of Blujepa for uncomplicated UTIs in female patients ≥12 years, ≥40 kg
• Mid-2025: Gradual market entry; limited pharmacy stocking as awareness builds
• December 2025: Expanded indication approved for uncomplicated urogenital gonorrhea (patients ≥12 years, ≥45 kg, with limited or no alternative treatment options)
• Early 2026: Increasing prescriber adoption, but pharmacy stocking still inconsistent nationwide

Prescribing Implications

When to Consider Blujepa

Blujepa fills specific clinical niches where its novel mechanism provides genuine value:

• Fluoroquinolone-resistant UTIs: Gepotidacin's binding site on DNA gyrase and topoisomerase IV is distinct from fluoroquinolones, meaning cross-resistance is not established
• Patients with multi-drug resistant uropathogens: Activity against E. coli, K. pneumoniae, C. freundii complex, S. saprophyticus, and E. faecalis
• Gonorrhea with limited options: Oral treatment alternative when injectable Ceftriaxone is not feasible or when resistance is a concern
• Sulfa or beta-lactam allergies: Gepotidacin's novel class avoids cross-reactivity with common antibiotic allergens

Dosing Quick Reference

• Uncomplicated UTI: 1,500 mg (two 750 mg tablets) orally twice daily for 5 days, taken after meals
• Uncomplicated urogenital gonorrhea: 3,000 mg (four 750 mg tablets) followed by 3,000 mg approximately 12 hours later

Key Safety Considerations

• QTc prolongation: Avoid in patients with history of QTc prolongation, pre-existing cardiac disease, or concomitant use of QTc-prolonging drugs
• CYP3A4 interactions: Contraindicated with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, ritonavir); strong inducers (rifampin, carbamazepine) may reduce efficacy
• Renal impairment: Avoid in severe renal impairment due to increased drug exposure
• Hepatic impairment: Avoid in severe hepatic impairment
• GI effects: Diarrhea (16%), nausea (9%), and abdominal pain (4%) are the most common adverse reactions

For detailed pharmacology, see our guide on how Blujepa works and Blujepa drug interactions.

The Availability Picture

The primary barriers to patient access are:

1. Low pharmacy stocking: As a new, single-source brand product, many retail pharmacies — particularly large chains — do not routinely stock Blujepa
2. High acquisition cost: Wholesale cost makes pharmacies hesitant to maintain inventory without guaranteed demand
3. Prior authorization requirements: Many commercial and Medicare Part D plans require PA, creating delays of 24-72 hours
4. Step therapy mandates: Some payers require documented failure of first-line agents (Nitrofurantoin, TMP-SMX) before approving Blujepa

Cost and Access Considerations

• Cash price: $400-$600 for a 5-day UTI course (10 tablets)
• Gonorrhea course: Higher cost (16 tablets needed)
• Insurance: Coverage varies; brand-only formulary tier with frequent PA requirements
• GSK patient assistance: GSK For You program available for eligible uninsured/underinsured patients (gskforyou.com, 1-888-825-5249)

For a patient-facing resource on cost reduction, refer patients to our guide to saving money on Blujepa.

Tools and Resources for Providers

Medfinder for Providers

Medfinder's provider tools allow you to check pharmacy-level Blujepa availability in your patient's area. This can be integrated into prescribing workflows to route prescriptions to pharmacies that actually have the medication in stock.

Pre-Prescribing Workflow

To minimize patient frustration and treatment delays:

1. Check Blujepa availability at local pharmacies using Medfinder before prescribing
2. Initiate prior authorization early — ideally when the treatment decision is made, not after the prescription is sent
3. Provide patients with backup options (e.g., "If the pharmacy can't fill this within 24 hours, call us and we'll prescribe Nitrofurantoin instead")
4. Consider independent pharmacies and hospital outpatient pharmacies, which are more likely to stock newer agents

Alternative Agents

When Blujepa is not accessible, established alternatives include:

• Nitrofurantoin (Macrobid): First-line for uUTI, $10-$30 generic
• TMP-SMX (Bactrim): First-line for uUTI where local resistance rates are <20%, $5-$20 generic
• Fosfomycin (Monurol): Single-dose option for uUTI, $40-$80
• Ceftriaxone: Standard of care for gonorrhea, $10-$50 injection

See our detailed comparison in the alternatives guide.

Looking Ahead

Several factors should improve Blujepa access throughout 2026:

• Increased prescriber awareness: As more clinicians become familiar with Gepotidacin, pharmacy demand will drive better stocking
• Gonorrhea indication adoption: The December 2025 expanded approval provides an oral option where previously only injectables existed, potentially broadening use
• Payer formulary updates: As clinical data matures and utilization grows, payer coverage policies may become more favorable
• Antimicrobial stewardship programs: Hospital and health system formulary committees are evaluating Blujepa for inclusion, which will improve institutional availability

Final Thoughts

Blujepa represents a meaningful advancement in antimicrobial therapy — a new mechanism of action in an era of increasing resistance. While current access barriers are real, they're driven by market dynamics rather than supply shortages. By using tools like Medfinder for Providers, initiating prior authorizations proactively, and counseling patients on pharmacy options, prescribers can help bridge the gap between Blujepa's clinical promise and its real-world availability.